GlobeNewswire by notified

Lassila & Tikanoja’s Annual Report 2022 has been published

Share


Lassila & Tikanoja plc
Stock exchange release
1 March 2023 1.00 pm

Lassila & Tikanoja’s Annual Report 2022 has been published

Lassila & Tikanoja’s Annual Report for 2022 has been published at www.lt.fi/en/investors/reports-and-presentations. The annual report consists of the Annual Review 2022 and the Financial Review 2022.

The Financial Review includes the Board of Directors’ report, Financial Statements for the year 2022 and the Auditor’s report, Corporate Governance Statement and the Remuneration Report.

Lassila & Tikanoja publishes the Financial Review in accordance with European Single Electronic Format (ESEF) reporting requirements with the format of the report being Extensible Hypertext Markup Language (XHTML). In line with the ESEF requirements, the primary statements have been labelled with XBRL tags and notes to the financial statements have been labelled with XBRL block tags.

The Financial Review is attached to this release as an XHTML file as well as a PDF file and it is available on www.lt.fi/en.

The Annual Review 2022 includes a sustainability report in accordance with the GRI standards.

LASSILA & TIKANOJA PLC

Eero Hautaniemi
President and CEO

Additional information:

Eero Hautaniemi, President and CEO, tel. +358 10 636 2810

Valtteri Palin, CFO, tel. +358 40 734 7749

Lassila & Tikanoja is a service company that is putting the circular economy into practice. Together with our customers, we keep materials and properties in productive use for as long as possible and we enhance the use of raw materials and energy. This is to create more value with the circular economy for our customers, personnel and society in a broader sense. Achieving this also means growth in value for our shareholders. Our objective is to continuously grow our actions’ carbon handprint, our positive effect on the climate. We assume our social responsibility by looking after the work ability of our personnel as well as offering jobs to those who are struggling to find employment, for example. With operations in Finland and Sweden, L&T employs 8,371 people. In 2022, the company’s net sales amounted to EUR 844.1 million. L&T is listed on Nasdaq Helsinki.

Distribution:

Nasdaq Helsinki

Major media

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS23.3.2023 01:31:57 CET | Press release

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?” the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On the second question, “Does the clinical data from the placebo-controlled study and available long-term extension study results, with additional supporting res

GN Store Nord announces change to the Board of Directors22.3.2023 22:22:29 CET | Press release

Due to sudden serious health issues in the family, Montserrat Maresch Pascual has decided to step down from the Board of Directors of GN Store Nord A/S. The Chairmanship assesses that the remaining five members of the Board possess all the relevant competencies and experience to govern the company. Consequently, GN’s Board of Directors as of today consists of Jukka Pekka Pertola (Chair), Klaus Holse (Deputy chair), Anette Weber, Hélène Barnekow, Ronica Wang, and members elected by the employees: Leo Larsen, Cathrin Inge Hansen, and Claus Holmbeck-Madsen. For further information, please contact: Investor Relations Anne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring pe

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 202222.3.2023 22:05:00 CET | Press release

ERYTECH Provides Business and Financial Update for the Fourth Quarterand Full Year 2022 Combination with Pherecydesannounced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022Cash and cash equivalents of €38.8million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France),March 22, 2023– ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial updatefor thefourth quarterand full year of2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer, we have pursued during 2022 a consistent strategy to maximize the remaining value for our shareholders through strategic partnering. We sold our US manufacturing site, sharply

Hvidbjerg Banks ordinære generalforsamling den 22. marts 202322.3.2023 21:48:49 CET | pressemeddelelse

Formand Henrik H. Galsgaard udpegede advokat Rasmus Kronborg, Thisted til dirigent i henhold til vedtægternes § 9. Rasmus Kronborg takkede for valget og konstaterede, at generalforsamlingen var korrekt indvarslet og beslutningsdygtig med hensyn til generalforsamlingens dagsorden, som blev gennemgået. Dagsordenens punkt 1: Formand Henrik H. Galsgaard aflagde på bestyrelsens vegne mundtlig beretning om bankens virksomhed i det forløbne år. På grund af kommende kapitalkrav forventes der ikke udbetalt udbytte i de kommende år. Der var ikke kommet bemærkninger eller spørgsmål, hvorefter dirigenten konstaterede, at beretningen var taget til efterretning. Dagsordenens punkt 2 og 3: Bankdirektør Jens Odgaard fremlagde årsrapporten til godkendelse og årsrapporten blev godkendt. Årets resultat t.kr. 25.172 blev vedtaget overført således: Udbytte 0 Rente hybrid kernekapital 975 Henlagt til egenkapitalen 24.197 I alt anvendt 25.172 Dagsordenens punkt 4: Bestyrelsesformand Henrik H. Galsgaard freml

CNH Industrial: Periodic Report on $300 Million Buyback Program. Completion of Second $50 million tranche and launch of Third $50 million tranche22.3.2023 21:30:00 CET | Press release

London, March 22, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has completed the second tranche of its $50 million share buyback (the “Second Tranche”) in the framework of its $300 million common share buyback program with the transaction described in the table below. The transaction, completed on March 13, 2023, reported in aggregate, was based on automatic orders placed with the Company’s broker (who made its trading decisions as to the timing of the purchases independently of the Company based on instructions given before the commencement of the Company’s closed period under the applicable regulations). After the purchases announced today and considering those previously executed under the Second Tranche, the total invested amount is approximately €46,863,453.43 ($49,999,997.50) for a total amount of 3,065,368 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) exclu